Liraglutide biosimilar - CinnaGen

Drug Profile

Liraglutide biosimilar - CinnaGen

Alternative Names: CinnaGen-liraglutide

Latest Information Update: 28 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CinnaGen
  • Class Antihyperglycaemics; Glucagon-like peptides; Obesity therapies
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Type 2 diabetes mellitus

Most Recent Events

  • 02 Feb 2018 CinnaGen plans a phase III trial to compare the safety and efficacy of liraglutide biosimilar to liraglutide in patients with Type 2 diabetes mellitus (SC) in April 2018 (NCT03421119)
  • 01 Jan 2018 Clinical trials in Type-2 diabetes mellitus in Iran (SC), before January 2018 (NCT03421119)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top